|Author(s)/Faculty: Sanjiv S. Agarwala, MD; Omid Hamid, MD; Georgina V. Long, BSc, PhD, MBBS, FRACP; Steven J. O'Day, MD; Alexander Shoushtari, MD; Allison Betof Warner, MD, PhD|
|Advances in BRAF-targeted agents and their integration into treatment algorithms for patients diagnosed with BRAF-mutated melanoma have dramatically enhanced clinical outcomes. However, for patients diagnosed with unresectable disease, challenges exist for identifying those who will benefit from first-line targeted therapy versus immune-based therapies. Additionally, the number of advanced melanoma cases has increased by over 50% during the previous decade. This disease can progress quickly, with spread to the regional lymph nodes or distant organs being associated with a poor prognosis. Over the past decade, the US Food and Drug Administration's approval of several targeted agents and immune checkpoint inhibitors (ICI) has significantly shifted treatment paradigms for advanced melanoma. The National Comprehensive Cancer Network (NCCN) Guidelines now recommend ICI-based therapy as a preferred frontline option for newly diagnosed unresectable or metastatic disease. Lastly, targeted and immune-based therapies have advanced clinical outcomes for patients with melanoma. As further therapies are evaluated and approved, challenges in selecting patients who may receive optimal benefit from evolving and current therapies, sequencing of therapies, management of adverse events, and utilizing therapies as mono- or combination-therapy have arisen. Furthermore, the treatment of patients with brain or liver metastases or with uveal melanoma provide challenges regarding the treatment and management algorithm selection.
In this educational activity, experts in the field review the patient, disease, and/or treatment characteristics that may help in clinical decision-making for patients with newly diagnosed BRAF-mutated melanoma. They also evaluate the latest clinical evidence pertaining to the use of targeted and/or checkpoint inhibitors in patients with unresectable BRAF-mutated disease. Faculty also assess the latest long-term and real-world evidence regarding ICI therapy for patients with newly diagnosed advanced melanoma. In addition, experts discuss clinical cases to provide guidance on identifying optimal candidates for frontline therapy, decisions regarding monotherapy versus combination therapy, as well as appropriate treatment duration and management of immune-related adverse events. And finally, experts in the field examine emerging combinations and cellular therapies for the treatment of patients with melanoma and assess the latest evidence regarding the management of patients with melanoma in challenging clinical scenarios.